Valeant Pharmaceuticals Intl Inc Stock Analysis, Valuation (NYSE:VRX)

Add to My Stocks
$14.23 $0.16 (1.14%) VRX stock closing price Sep 21, 2017 (Closing)
Watch Robo Advisor Video of VRX Stock Analysis
Valeant Pharmaceuticals Intl Inc
Updated on : Sep 21, 2017
previous close
VRX 14.2 (0%)
S&P 500 2500.6 (0%)
Closing Price On: Sep 21, 2017
stock rating
RATING: ★★★★★★★★★★ (0/5)
Industry :
Medical-Drugs
Sector :
Medical
5 Quarter Revenue
Revenue Growth
2017-Q2
$billion
%
YOY GROWTH
Compared to the industry
Operating Profit
Operating Margin:
-3.5%
Sector Average:
-2.3%
5 Quarter Net Profit
Net Margins
2017-Q2
%
LTM Margin
Debt/Equity Ratio
Debt:
28.46B
Debt/Equity Ratio:
 7.06
Compared to the industry
Cash Flow
Operating cash flow:
$268M
Net Income:
-$38M
PROS      CONS
FCF Margin
PE Valuation
PS Valuation
Recent Growth
Operating Margins
Net Margins
High Debt Burden
ROIC
ROE
Rating: ★★★★★★★★★★ (0/5)
Relative Valuation
VRX PS :
0.5
Industry PS :
5.3
Sector:   Medical.   *PE adjusted for one time items.
Other Metrics
Return on Invested Capital:
-0.5%
Return on Equity:
-27.3%
Free Cash Flow Margin:
106.4%
Double Tap To Exit Full Screen
0:00
/

VRX Stock Analysis

1612 6 2

View Valeant Pharmaceuticals Intl Inc stock analysis video. This is our analyst opinion covering the buy and sell arguments for VRX stock.

Valeant Pharmaceuticals Intl Inc Stock Rating 3.1/5

Our Valeant Pharmaceuticals Intl Inc stock opinion is based on fundamentals of the company. This Valeant Pharmaceuticals Intl Inc stock analysis is based on latest 2017 Q2 earnings. The stock price analysis takes into account the company's valuation metrics.

Should you buy VRX stock?

  • The price to earnings multiple of 2.1 is attractive when compared with the industry average PE ratio of 22.7.
  • When compared with the Medical-Drugs industry average PS ratio of 5.3, the price-to-sales ratio of 0.5 for VRX stock is attractive.
  • Valeant Pharmaceuticals Intl Inc has a healthy FCF (Free Cash Flow) margin of 106.4%.

Should you sell VRX stock?

  • Valeant Pharmaceuticals Intl Inc sales shrank by -7.7% year-over-year in 2017 Q2.
  • Valeant Pharmaceuticals Intl Inc registered a negative operating margin of -3.5% (average) over the Trailing Twelve Months (TTM).
  • Valeant Pharmaceuticals Intl Inc registered an average TTM Net loss of -12.4%.
  • Valeant Pharmaceuticals Intl Inc is debt laden and has a high debt/equity ratio of  7.06.
  • Valeant Pharmaceuticals Intl Inc has a negative ROIC (Return on Invested Capital) of -0.5%.
  • Valeant Pharmaceuticals Intl Inc has a negative return on equity of -27.3%. This indicates that the firm is inefficient at generating profits.

Comments on this video and Valeant Pharmaceuticals Intl Inc stock